Literature DB >> 34079394

Step by Step: Managing the Complications of Cirrhosis.

Irene C Perez1, Fabian J Bolte1, William Bigelow1, Zachary Dickson2, Neeral L Shah2.   

Abstract

According to the Centers for Disease Control and Prevention, chronic liver disease and cirrhosis is the 11th leading cause of death in the United States. Common causes of chronic liver disease include alcohol, viral hepatitis, and non-alcoholic steatohepatitis (NASH). Inflammation is a critical driver in the progression of liver disease to liver fibrosis and ultimately cirrhosis. While the severity of chronic liver disease extends over a continuum, the management is more easily differentiated between compensated and decompensated cirrhosis. In this review, we discuss pathophysiology, clinical features and management of common complications of liver cirrhosis based on literature review and the current clinical practice guidelines of the American Association for the Study of Liver Diseases (AASLD).
© 2021 Perez et al.

Entities:  

Keywords:  chronic liver disease; cirrhosis; compensated cirrhosis; decompensated cirrhosis; end-stage liver disease; hepatorenal syndrome

Year:  2021        PMID: 34079394      PMCID: PMC8164676          DOI: 10.2147/HMER.S278032

Source DB:  PubMed          Journal:  Hepat Med        ISSN: 1179-1535


  117 in total

1.  Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.

Authors:  Yonghui Huang; Bin Chen; Ni Liu; Nan Li; Haitao Dao; Wei Chen; Jianyong Yang
Journal:  Int J Clin Pharmacol Ther       Date:  2017-06       Impact factor: 1.366

2.  Care of patients with ascites.

Authors:  B A Runyon
Journal:  N Engl J Med       Date:  1994-02-03       Impact factor: 91.245

3.  Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.

Authors:  Masatoshi Kudo; Guohong Han; Richard S Finn; Ronnie T P Poon; Jean-Frederic Blanc; Lunan Yan; Jijin Yang; Ligong Lu; Won-Young Tak; Xiaoping Yu; Joon-Hyeok Lee; Shi-Ming Lin; Changping Wu; Tawesak Tanwandee; Guoliang Shao; Ian B Walters; Christine Dela Cruz; Valerie Poulart; Jian-Hua Wang
Journal:  Hepatology       Date:  2014-09-29       Impact factor: 17.425

4.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 5.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

Review 6.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

7.  Transfusion with Cryoprecipitate for Very Low Fibrinogen Levels Does Not Affect Bleeding or Survival in Critically Ill Cirrhosis Patients.

Authors:  Isadore M Budnick; Jessica P E Davis; Anirudh Sundararaghavan; Samuel B Konkol; Chelsea E Lau; James P Alsobrooks; Matthew J Stotts; Nicolas M Intagliata; Ton Lisman; Patrick G Northup
Journal:  Thromb Haemost       Date:  2022-03-03       Impact factor: 6.681

Review 8.  Cirrhosis and autoimmune liver disease: Current understanding.

Authors:  Rodrigo Liberal; Charlotte R Grant
Journal:  World J Hepatol       Date:  2016-10-08

9.  Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.

Authors:  Rajiv Jalan; Javier Fernandez; Reiner Wiest; Bernd Schnabl; Richard Moreau; Paolo Angeli; Vanessa Stadlbauer; Thierry Gustot; Mauro Bernardi; Rafael Canton; Agustin Albillos; Frank Lammert; Alexander Wilmer; Rajeshwar Mookerjee; Jordi Vila; Rita Garcia-Martinez; Julia Wendon; José Such; Juan Cordoba; Arun Sanyal; Guadalupe Garcia-Tsao; Vicente Arroyo; Andrew Burroughs; Pere Ginès
Journal:  J Hepatol       Date:  2014-02-12       Impact factor: 25.083

Review 10.  Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.

Authors:  Tong Li; Wenbo Ke; Ping Sun; Xiang Chen; Ajay Belgaumkar; Yuanjian Huang; Wenjing Xian; Jinjin Li; Qichang Zheng
Journal:  BMJ Open       Date:  2016-05-04       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.